Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by G Fioritoni
Role of BCL2L10 Methylation and TET2 Mutations in Higher Risk Myelodysplastic Syndromes Treated With 5-Azacytidine
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Related publications
Prognostic Role of TET2 Deficiency in Myelodysplastic Syndromes: A Meta-Analysis
Oncotarget
Oncology
Somatic Mutations, DNA Methylation, and Expression of DNA Repair Genes in Arabidopsis Thaliana Treated With 5-Azacytidine
Biologia Plantarum
Horticulture
Plant Science
Comparison of Risk Stratification Tools in Predicting Outcomes of Patients With Higher-Risk Myelodysplastic Syndromes Treated With Azanucleosides
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
The Prognostic Significance of Chromosome 17 Abnormalities in Patients With Myelodysplastic Syndrome Treated With 5‐azacytidine: Results From the Hellenic 5‐azacytidine Registry
Cancer Medicine
Cancer Research
Nuclear Medicine
Radiology
Imaging
Oncology
IDH1 and IDH2 Mutations in Myelodysplastic Syndromes and Role in Disease Progression
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Correction: Mutations in the DNA Methylation Pathway and Number of Driver Mutations Predict Response to Azacitidine in Myelodysplastic Syndromes
Oncotarget
Oncology
The Augmented Expression of the Cytidine Deaminase Gene by 5-Azacytidine Predicts Therapeutic Efficacy in Myelodysplastic Syndromes
Oncotarget
Oncology
Effectiveness of 5-Azacytidine in Older Patients With High-Risk Myelodysplastic Syndromes and Oligoblastic Acute Myeloid Leukemia: A Retrospective Analysis of the Hellenic (Greek) MDS Study Group
Journal of Geriatric Oncology
Gerontology
Geriatrics
Oncology
Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
